|[August 13, 2014]
Amneal Pharmaceuticals Announces Four New Generics
BRIDGEWATER, N.J. --(Business Wire)--
Amneal Pharmaceuticals' fast-growing portfolio of approved generic drugs
is expanding once again with the launch of four new medications.
Representing multiple therapeutic categories, these products accounted
for $900 million annually in U.S. sales as of June 2014, according to
IMS Health market data.
Acyclovir ointment, USP is available in 5% strength. Sold in
30-gram tubes, each gram of ointment contains 50 mg of acyclovir. The
Amneal generic is an AB-rated therapeutic equivalent to Zovirax®
Atovaquone oral suspension, USP, the first-to-market generic, is
available in 750 mg/5 mL strength. The bright yellow, citrus-flavored
liquid comes packaged in 210 mL (8 fl. oz.) bottles. The Amneal
medication is an AB-rated therapeutic equivalent to Mepron®
Clindamycin palmitate hydrochloride for oral solution, USP
(Pediatric) is available in 75 mg/5 mL reconstituted strength.
Mixing the powder with water provides 100 mL of a clear, cherry-flavored
solution. The Amneal product is an AA-rated therapeutic equivalent to
Cleocin Pediatric®. Click
here for full prescribing information.
Oxycodone hydrochloride tablets, USP (C-II) are available in 5
mg, 10 mg, 15 mg, 20 mg, or 30 mg strength in 100-count bottles. The
Amneal generic is AB-rated and therapeutically equivalent to Roxicodone®.
These four products are now shipping and available through wholesalers,
distributors, and directly to the trade.
"Introducing these four products in the market aligns with our strategic
focus on extending our generic offerings across all dosage forms," said
Chirag Patel (News - Alert), Co-CEO and Co-Chairman of Amneal. "Currently, we have 125
ANDAs filed with the U.S. FDA across numerous dosage forms, including
transdermal, oral liquid, topical, injectable, oral solid, ophthalmic
and otic. These new medications will further diversify our expansive
About Amneal Pharmaceuticals LLC
Amneal Pharmaceuticals LLC is a U.S.-based manufacturer of generic
pharmaceuticals. Known as "Generic's New Generation®", Amneal
prides itself on its unwavering commitment to quality, meaningful
business relationships, and its innovative approach to maximizing value
for all stakeholders. Extensive investment in R&D, an intelligently
aggressive expansion strategy, and focus on vertical integration are key
contributors to the company's impressive growth over the past several
years. Amneal is headquartered in Bridgewater, New Jersey with
manufacturing, R&D, packaging, sales and distribution facilities
throughout the U.S. as well as abroad. For more information, visit www.amneal.com.
All trademarks are property of their respective owners.
[ Back To Technology News's Homepage ]